WWP-2X (Tirz)

WWP-2X (Tirz) - GLP-1 / GIP Dual Agonist Research Peptide

WWP-2X (Tirz) is a synthetic research peptide that activates two different gut-hormone receptors at once: GLP-1 (the same receptor semaglutide hits) and GIP (glucose-dependent insulinotropic polypeptide). It was the first dual incretin agonist engineered for once-weekly administration. Because it adds GIP to the GLP-1 mechanism that semaglutide already established, tirzepatide is the most common reference compound for dual-agonist research and the direct precursor to the triple agonist retatrutide.

Why Dual Agonism Matters

GLP-1 on its own addresses only half of the gut-hormone signal the body releases after a meal. GIP contributes the other half: it amplifies insulin secretion, acts on adipose (fat) tissue, and appears to reduce some of the nausea signaling that comes from GLP-1 in isolation. By combining both receptor activities in a single molecule, tirzepatide lets researchers study the two signals together rather than running them as separate experiments.

Tirzepatide vs Semaglutide vs Retatrutide

All three peptides come from the same GLP-1 research lineage but target different receptor combinations.

The practical research distinction: tirzepatide added GIP to what semaglutide was already doing, and retatrutide added glucagon on top of that. Direct head-to-head data (SURMOUNT-5, published 2024) showed tirzepatide produced larger body-composition endpoints than semaglutide over 72 weeks.

Research Applications

Tirzepatide is used in studies examining:

• Body-composition changes under sustained dual-incretin stimulation
• How the added GIP signal changes glucose and insulin dynamics relative to GLP-1-only agonists
• Appetite and satiety models
• Cardiovascular and metabolic markers in the SURMOUNT and SURPASS trial frameworks
• Dose-response characterization across published trial doses (5, 10, 15mg)
• Reference comparisons against semaglutide (single agonist) and retatrutide (triple agonist)

Specifications

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Tirzepatide are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Tirzepatide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Tirzepatide Research

What is the difference between tirzepatide and retatrutide?

Tirzepatide activates GLP-1 and GIP. Retatrutide activates those same two receptors plus glucagon, making it a triple agonist. Retatrutide is still in Phase 3 clinical trials.

What does tirzepatide do in metabolic studies?

It activates GLP-1 and GIP receptors simultaneously. Together these receptors regulate glucose-dependent insulin release, glucagon suppression, gastric emptying, appetite signaling in the hypothalamus, and adipose-tissue metabolism. Study endpoints most commonly tracked are HbA1c, fasting glucose, body composition, and ad-libitum caloric intake.

Is tirzepatide FDA approved?

Research-grade tirzepatide sold by WWP is not a branded drug product and is not approved or intended for human consumption. Every vial is labeled and sold strictly for laboratory and research use only.

How is tirzepatide stored?

Unopened vials are stored at 2-8°C (refrigerator temperature) and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.

Purity Guarantee

Every batch is supplied to a ≥99% purity specification. Send us a COA from any independent test and we’ll issue $300 store credit regardless of what it shows.